AI-powered cardiometabolic data platform for clinical care coordination
Welldoc operates a healthcare AI platform that ingests fragmented patient data and surfaces clinical insights to care teams. The tech stack is heavily cloud-native (Databricks, Azure, AWS, Spark) with mature ML tooling (RAG, GPT-4, LLaMA, vector DBs), yet the company is wrestling with core data-platform challenges—fragmented schema, slow adoption, and algorithm deployment friction. This mismatch between advanced LLM infrastructure and fundamental data-architecture pain points suggests ongoing architectural debt in their core ingest and ETL layer.
Welldoc builds an AI platform designed for cardiometabolic care coordination, connecting patients, clinical teams, and health plans around real-time patient data and predictive coaching. Founded in 2005 and based in Columbia, Maryland, the company operates at 51–200 employees with active hiring across engineering, data, and sales. The platform ingests data from EHRs, patient apps (iOS, Android), and third-party sources, then surfaces clinical decision support and behavioral interventions. Regulatory compliance, complex workflow design, and data-model standardization are core operational constraints.
Welldoc deploys GPT-4, LLaMA, RAG pipelines, and CrewAI for clinical insights. They use vector databases (Weaviate, Pinecone, FAISS) and LangChain/LangGraph for orchestration, running workloads on Databricks and Azure.
Welldoc uses Fivetran for data ingestion, Azure Data Factory and Synapse for ETL, Databricks for analytics, and Delta Sharing for secure data movement. MongoDB and Cosmos DB handle operational data.
Welldoc's technology stack, projects, and hiring signals are inferred from public hiring and company data — career pages, public listings, and company web presence — then clustered and de-duplicated. Figures are estimates that refresh over time. Read our full methodology →
This is not an official vendor or customer list. It is a technology-adoption signal inferred from public data, intended for B2B research.